Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Stege

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Overcoming multidrug resistance by RNA interferenceAlexandra Stege, Andrea Krühn, Hermann Lage
Cancer Gene Therapy|September 18, 2004
Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interferenceAlexandra Stege, Axel Priebsch, Christiane Nieth, et al.
FEBS Letters|June 14, 2003
Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)Christiane Nieth, Axel Priebsch, Alexandra Stege, et al.
Biochemical and Biophysical Research Communications|August 1, 2006
RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cellsVerena Materna, Alexandra Stege, Pawel Surowiak, et al.
Oncogene|December 9, 2003
Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cellsAnke Wichert, Alexandra Stege, Yutaka Midorikawa, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 20, 2007
Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNAUlrike Stein, Wolfgang Walther, Alexandra Stege, et al.
Oligonucleotides|September 19, 2006
Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cellsAxel Priebsch, Franziska Rompe, Holger Tönnies, et al.
Scientific Reports|April 29, 2025
Author Correction: A multicenter study of asymmetric and symmetric dimethylarginine as predictors of mortality risk in hospitalized COVID-19 patientsJuliane Hannemann, Anne Zink, Yoana Mileva, et al.
Scientific Reports|July 8, 2024
A multicenter study of asymmetric and symmetric dimethylarginine as predictors of mortality risk in hospitalized COVID-19 patientsJuliane Hannemann, Anne Zink, Yoana Mileva, et al.
Diagnostic and Prognostic Research|September 12, 2023
Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control studyJane I Grove, Camilla Stephens, M Isabel Lucena, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Overcoming multidrug resistance by RNA interferenceAlexandra Stege, Andrea Krühn, Hermann Lage
Cancer Gene Therapy|September 18, 2004
Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interferenceAlexandra Stege, Axel Priebsch, Christiane Nieth, et al.
FEBS Letters|June 14, 2003
Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)Christiane Nieth, Axel Priebsch, Alexandra Stege, et al.
Biochemical and Biophysical Research Communications|August 1, 2006
RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cellsVerena Materna, Alexandra Stege, Pawel Surowiak, et al.
Oncogene|December 9, 2003
Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cellsAnke Wichert, Alexandra Stege, Yutaka Midorikawa, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 20, 2007
Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNAUlrike Stein, Wolfgang Walther, Alexandra Stege, et al.
Oligonucleotides|September 19, 2006
Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cellsAxel Priebsch, Franziska Rompe, Holger Tönnies, et al.
Scientific Reports|April 29, 2025
Author Correction: A multicenter study of asymmetric and symmetric dimethylarginine as predictors of mortality risk in hospitalized COVID-19 patientsJuliane Hannemann, Anne Zink, Yoana Mileva, et al.
Scientific Reports|July 8, 2024
A multicenter study of asymmetric and symmetric dimethylarginine as predictors of mortality risk in hospitalized COVID-19 patientsJuliane Hannemann, Anne Zink, Yoana Mileva, et al.
Diagnostic and Prognostic Research|September 12, 2023
Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control studyJane I Grove, Camilla Stephens, M Isabel Lucena, et al.
Pageof 2